Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 DDI study with rifampicin or itraconazole
NCT06658964Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JMKX003142 in autosomal dominant polycystic kidney disease (ADPKD) (2 cohorts), sponsored by Jemincare. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06658964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658964.